Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastrointest Surg. Apr 27, 2022; 14(4): 304-314
Published online Apr 27, 2022. doi: 10.4240/wjgs.v14.i4.304
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flow chart of patient selection. AEG: Adenocarcinoma of the esophagogastric junction.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Comparison of overall survival rates between the laparoscopic-assisted transhiatal gastrectomy and open transhiatal gastrectomy groups. A. Comparison of overall survival rates between the laparoscopic-assisted transhiatal gastrectomy (LTG) and open transhiatal gastrectomy (OTG) groups for all patients; B: Comparison of overall survival rates between the LTG and OTG groups for stage I patients; C: Comparison of overall survival rates between the LTG and OTG groups for stage II patients; D: Comparison of overall survival rates between the LTG and OTG groups for stage III patients. CI: Confidence interval; HR: Hazard ratio.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Comparison of disease-free survival rates between the laparoscopic-assisted transhiatal gastrectomy and open transhiatal gastrectomy groups. A: Comparison of disease-free survival rates between the laparoscopic-assisted transhiatal gastrectomy (LTG) and open transhiatal gastrectomy (OTG) groups for all patients; B: Comparison of disease-free survival rates between the LTG and OTG groups for stage I patients; C: Comparison of disease-free survival rates between the LTG and OTG groups for stage II patients; D: Comparison of disease-free survival rates between the LTG and OTG groups for stage III patients. CI: Confidence interval; HR: Hazard ratio.